AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
104_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
29_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
Employee_NN
costs_VPRT
The_DT
average_JJ
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
is_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
table_NN
below_PLACE
._.
In_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
this_DEMP
includes_VPRT
part-time_JJ
employees_NN
:_:
Employees_NN
2004 2003 2002_CD
Average_JJ
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
in_PIN
:_:
UK_NN
11,500_CD
11,100_CD
10,900_CD
Continental_NN
Europe_NN
25,600_CD
23,900_CD
23,500_CD
The_DT
Americas_NN
18,500_CD
17,900_CD
17,800_CD
Asia_NN
,_,
Africa_NN
&_CC
Australasia_NN
8,600_CD
8,100_CD
7,200_CD
Continuing_VBG
operations_NOMZ
64,200_CD
61,000_CD
59,400_CD
The_DT
number_NN
of_PIN
people_NN
employed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
at_PIN
the_DT
end_NN
of_PIN
2004_CD
was_VBD [BEMA]
64,200_CD
2003_CD
62,600_CD
,_,
2002_CD
59,200_CD
._.
The_DT
costs_NN
incurred_VBN [WZPAST]
during_PIN
the_DT
year_NN
in_PIN
respect_NN
of_PIN
these_DEMO
employees_NN
were_VBD
:_:
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Salaries_NN
4,078_CD
3,587_CD
3,022_CD
Social_NN
security_NOMZ
costs_NN
644 526 505_CD
Pension_NN
costs_NN
266 272 220_CD
Other_JJ
employment_NOMZ
costs_NN
303 360 246_CD
5,291_CD
4,745_CD
3,993_CD
Employee_NN
costs_NN
above_PLACE
do_VPRT
not_XX0
include_VB
severance_NN
costs_NN
._.
The_DT
Directors_NN
believe_VPRT [PRIV] [THATD]
that_DEMP
,_,
together_RB
with_PIN
the_DT
basic_JJ
salary_NN
system_NN
,_,
the_DT
Groups_NN
employee_NN
incentive_NN
schemes_NN
provide_VPRT
competitive_JJ
and_PHC
marketrelated_JJ
packages_NN
to_TO
motivate_VB
employees_NN
._.
They_TPP3
should_NEMD [SPAU]
also_RB
align_VB
the_DT
interests_NN
of_PIN
employees_NN
with_PIN
those_DEMO
of_PIN
shareholders_NN
,_,
as_IN
a_DT
whole_JJ
,_,
through_PIN
long_JJ
term_NN
share_NN
ownership_NN
in_PIN
the_DT
Company_NN
._.
The_DT
Groups_NN
current_JJ
UK_NN
,_,
Swedish_NN
and_PHC
US_FPP1
schemes_NN
are_VPRT [PASS]
described_VBN
below_PLACE
:_:
other_JJ
arrangements_NOMZ
apply_VPRT
elsewhere_RB
._.
The_DT
AstraZeneca_NN
UK_NN
Performance_NN
Bonus_NN
Plan_NN
Employees_NN
of_PIN
participating_VBG
AstraZeneca_NN
UK_NN
companies_NN
are_VPRT [PASS]
invited_VBN
to_TO
participate_VB
in_PIN
this_DEMO
bonus_NN
plan_NN
which_WDT [WHSUB]
rewards_VPRT
strong_JJ
individual_JJ
performance_NN
._.
Bonuses_NN
are_VPRT [PASS]
paid_VBN
partly_DWNT
in_PIN
the_DT
form_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
the_DT
Company_NN
under_IN
the_DT
Inland_NN
Revenue_NN
approved_VBD
AstraZeneca_NN
AllEmployee_NN
Share_NN
Plan_NN
and_CC
up_RB
to_PIN
a_DT
maximum_JJ
annual_JJ
value_NN
of_PIN
3,000_CD
and_CC
partly_DWNT
in_PIN
cash_NN
._.
A_DT
tax_NN
efficient_JJ
share_NN
retention_NOMZ
scheme_NN
,_,
under_IN
which_WDT
employees_NN
leave_VPRT
their_TPP3
bonus_NN
shares_NN
in_PIN
trust_NN
for_PIN
three_CD
to_PIN
five_CD
years_NN
,_,
forms_NN
part_NN
of_PIN
the_DT
All-Employee_NN
Share_NN
Plan_NN
._.
The_DT
Company_NN
also_RB
offers_VPRT
UK_NN
employees_NN
the_DT
opportunity_NOMZ
to_TO
buy_VB
Partnership_NN
Shares_NN
Ordinary_NN
Shares_NN
under_IN
the_DT
All-Employee_NN
Share_NN
Plan_NN
._.
Employees_NN
may_POMD
invest_VB
up_RP
to_PIN
1,500_CD
over_IN
a_DT
12_CD
month_NN
accumulation_NOMZ
period_NN
and_PHC
purchase_NN
Partnership_NN
Shares_NN
in_PIN
the_DT
Company_NN
with_PIN
the_DT
total_JJ
proceeds_NN
at_PIN
the_DT
end_NN
of_PIN
the_DT
period_NN
._.
The_DT
purchase_NN
price_NN
for_PIN
the_DT
shares_NN
is_VPRT [BEMA]
the_DT
lower_JJ
of_PIN
the_DT
price_NN
at_PIN
the_DT
beginning_GER
or_CC
the_DT
end_NN
of_PIN
the_DT
12_CD
month_NN
period_NN
._.
A_DT
tax_NN
efficient_JJ
share_NN
retention_NOMZ
scheme_NN
is_VPRT [BEMA]
also_RB
available_PRED
in_PIN
respect_NN
of_PIN
Partnership_NN
Shares_NN
._.
At_PIN
the_DT
Companys_NN
AGM_NN
in_PIN
2002_CD
,_,
shareholders_NN
approved_VBD
the_DT
issue_NN
of_PIN
new_JJ
shares_NN
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
All-Employee_NN
Share_NN
Plan_NN
._.
The_DT
AstraZeneca_NN
Executive_NN
Annual_JJ
Bonus_NN
Scheme_NN
This_DEMO
scheme_NN
is_VPRT [BEMA]
a_DT
performance_NN
bonus_NN
scheme_NN
for_PIN
Directors_NN
and_CC
senior_JJ
employees_NN
who_WP [WHSUB]
do_VPRT
not_XX0
participate_VB
in_PIN
the_DT
AstraZeneca_NN
UK_NN
Performance_NN
Bonus_NN
Plan_NN
._.
Annual_JJ
bonuses_NN
are_VPRT [PASS]
paid_VBN
in_PIN
cash_NN
and_CC
reflect_VB [PRIV]
both_DT
corporate_JJ
and_PHC
individual_JJ
performance_NN
measures_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
has_VPRT
discretion_NOMZ
to_TO
reduce_VB
or_CC
withhold_VB
bonuses_NN
if_COND
business_NOMZ
performance_NN
falls_VPRT
sufficiently_RB
short_JJ
of_PIN
expectations_NOMZ
in_PIN
any_QUAN
year_NN
such_JJ
as_IN
to_TO
make_VB
the_DT
payment_NOMZ
of_PIN
bonuses_NN
inappropriate_JJ
._.
The_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
and_CC
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Plan_NN
UK_NN
employees_NN
may_POMD
make_VB
regular_JJ
monthly_JJ
savings_GER
contributions_NOMZ
over_IN
a_DT
three_CD
or_CC
five_CD
year_NN
period_NN
and_CC
may_POMD
apply_VB
for_PIN
options_NOMZ
to_TO
acquire_VB
AstraZeneca_NN
Ordinary_NN
Shares_NN
._.
Further_JJ
details_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
105_CD
29_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
continued_VBD
The_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
This_DEMP
is_VPRT [BEMA]
a_DT
share_NN
option_NOMZ
plan_NN
for_PIN
employees_NN
of_PIN
participating_VBG
AstraZeneca_NN
Group_NN
companies_NN
which_WDT [WHSUB]
was_VBD [BYPA]
approved_VBN
by_PIN
shareholders_NN
at_PIN
the_DT
Companys_NN
AGM_NN
in_PIN
2000_CD
._.
The_DT
first_JJ
grant_NN
of_PIN
options_NOMZ
occurred_VBD
in_PIN
August_NN
2000_CD
._.
The_DT
main_JJ
grant_NN
of_PIN
options_NOMZ
in_PIN
2004_CD
under_IN
the_DT
plan_NN
was_VBD [BEMA]
in_PIN
March_NN
,_,
with_PIN
a_DT
further_RB
,_,
smaller_JJ
grant_NN
in_PIN
August_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
sets_VPRT
the_DT
policy_NN
for_PIN
the_DT
Companys_NN
operation_NOMZ
of_PIN
the_DT
plan_NN
._.
Sweden_NN
In_PIN
Sweden_NN
an_DT
all_QUAN
employee_NN
performance_NN
bonus_NN
plan_NN
is_VPRT [BEMA]
in_PIN
operation_NOMZ
._.
The_DT
plan_NN
rewards_VPRT
strong_JJ
performance_NN
at_PIN
corporate_JJ
,_,
function_NOMZ
and_CC
individual_JJ
team_NN
level_NN
._.
Bonuses_NN
for_PIN
corporate_JJ
and_CC
function_NOMZ
performance_NN
are_VPRT [SPAU] [PASS]
always_RB
paid_VBN
in_PIN
the_DT
form_NN
of_PIN
AstraZeneca_NN
Ordinary_NN
Shares_NN
._.
Bonuses_NN
for_PIN
individual_JJ
team_NN
performance_NN
may_POMD
be_VB [PASS]
paid_VBN
in_PIN
Ordinary_NN
Shares_NN
or_CC
in_PIN
cash_NN
,_,
at_PIN
the_DT
employees_NN
discretion_NOMZ
._.
Existing_VBG
Ordinary_NN
Shares_NN
are_VPRT [PASS]
used_VBN
to_TO
pay_VB
bonuses_NN
awarded_VBN
under_IN
the_DT
plan_NN
._.
These_DEMP
are_VPRT [PASS]
purchased_VBN
in_PIN
the_DT
market_NN
._.
They_TPP3
must_NEMD
be_VB [PASS]
left_VBN
in_PIN
trust_NN
for_PIN
three_CD
years_NN
._.
The_DT
AstraZeneca_NN
Executive_NN
Annual_JJ
Bonus_NN
Scheme_NN
and_CC
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
both_DT
operate_VPRT
in_PIN
respect_NN
of_PIN
relevant_JJ
AstraZeneca_NN
employees_NN
in_PIN
Sweden_NN
._.
US_FPP1
In_PIN
the_DT
US_FPP1
,_,
there_EX
are_VPRT
two_CD
senior_JJ
staff_NN
incentive_NN
schemes_NN
,_,
under_IN
which_WDT
either_CC
AstraZeneca_NN
ADSs_NN
or_CC
stock_NN
appreciation_NOMZ
rights_NN
related_VBN [WZPAST]
to_PIN
AstraZeneca_NN
ADSs_NN
are_VPRT [PASS]
awarded_VBN
to_PIN
participants_NN
._.
There_EX
are_VPRT
currently_RB
approximately_RB
140_CD
participants_NN
in_PIN
these_DEMO
schemes_NN
._.
AstraZeneca_NN
ADSs_NN
necessary_JJ
to_TO
satisfy_VB
the_DT
awards_NN
under_IN
these_DEMO
schemes_NN
are_VPRT [PASS]
purchased_VBN
in_PIN
the_DT
market_NN
and_CC
no_SYNE
subscriptions_NOMZ
for_PIN
new_JJ
Ordinary_NN
Shares_NN
have_VPRT [PEAS]
been_VBN [PASS]
involved_VBN
._.
The_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
operates_VPRT
in_PIN
respect_NN
of_PIN
relevant_JJ
AstraZeneca_NN
employees_NN
in_PIN
the_DT
US_FPP1
._.
Share_NN
option_NOMZ
plans_VPRT
At_PIN
31_CD
December_NN
2004_CD
,_,
there_EX
were_VBD
options_NOMZ
outstanding_JJ
under_IN
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
the_DT
Astra_NN
Shareholder_NN
Value_NN
Incentive_NN
Plan_NN
,_,
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
,_,
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Plan_NN
and_CC
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
._.
1_CD
Summary_NN
of_PIN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
Eligibility_NOMZ
Any_QUAN
AstraZeneca_NN
employee_NN
may_POMD
be_VB [PASS]
recommended_VBN [SUAV]
from_PIN
time_NN
to_PIN
time_NN
for_PIN
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
The_DT
Remuneration_NOMZ
Committee_NN
sets_VPRT
the_DT
policy_NN
for_PIN
the_DT
Companys_NN
operation_NOMZ
of_PIN
the_DT
plan_NN
including_VBG [WZPRES]
as_IN
regards_VPRT
which_WDT
employees_NN
will_PRMD
be_VB [BEMA]
eligible_PRED
to_TO
participate_VB
._.
Grant_NN
of_PIN
options_NOMZ
Options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
at_PIN
any_QUAN
time_NN
other_JJ
than_PIN
during_PIN
a_DT
close_JJ
period_NN
._.
No_SYNE
options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
after_IN
the_DT
fifth_JJ
anniversary_NN
of_PIN
the_DT
approval_NN
of_PIN
the_DT
plan_NN
by_PIN
shareholders_NN
until_IN
the_DT
Remuneration_NOMZ
Committee_NN
has_VPRT [PEAS]
reviewed_VBN
the_DT
plan_NN
._.
The_DT
grant_NN
of_PIN
options_NOMZ
is_VPRT [BYPA]
supervised_VBN
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
which_WDT [WHSUB]
is_VPRT [PASS]
comprised_VBN
wholly_RB
of_PIN
Non-Executive_JJ
Directors_NN
._.
No_SYNE
payment_NOMZ
is_VPRT [PASS]
required_VBN [SUAV]
for_PIN
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
Options_NOMZ
may_POMD
be_VB [PASS]
granted_VBN [SUAV]
over_IN
AstraZeneca_NN
Ordinary_NN
Shares_NN
or_CC
ADSs_NN
._.
Acquisition_NOMZ
price_NN
The_DT
price_NN
per_PIN
Ordinary_NN
Share_NN
payable_JJ
upon_PIN
the_DT
exercise_NN
of_PIN
an_DT
option_NOMZ
will_PRMD
not_XX0
be_VB [BEMA]
less_PRED
than_PIN
an_DT
amount_NN
equal_JJ
to_PIN
the_DT
average_NN
of_PIN
the_DT
middle-market_JJ
closing_GER
price_NN
for_PIN
an_DT
Ordinary_NN
Share_NN
of_PIN
the_DT
Company_NN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
on_PIN
the_DT
three_CD
consecutive_JJ
dealing_VBG
days_NN
immediately_TIME
before_IN
the_DT
date_NN
of_PIN
grant_NN
or_CC
as_IN
otherwise_CONJ
agreed_VBN [SUAV] [PUBV]
with_PIN
the_DT
Inland_NN
Revenue_NN
._.
Where_RB
the_DT
option_NOMZ
is_VPRT [BEMA]
an_DT
option_NOMZ
to_TO
subscribe_VB
,_,
the_DT
price_NN
payable_JJ
upon_PIN
exercise_NN
can_POMD
not_XX0
be_VB [BEMA]
less_PRED
than_PIN
the_DT
nominal_JJ
value_NN
of_PIN
an_DT
Ordinary_NN
Share_NN
of_PIN
the_DT
Company_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
106_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
29_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
continued_VBD
Exercise_NN
of_PIN
options_NOMZ
An_DT
option_NOMZ
will_PRMD [SPAU]
normally_RB
be_VB [BEMA]
exercisable_PRED
between_PIN
three_CD
and_CC
10_CD
years_NN
following_VBG [WZPRES]
its_PIT
grant_NN
provided_VBD
any_QUAN
relevant_JJ
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
satisfied_VBN
._.
Options_NOMZ
may_POMD
be_VB [BYPA]
satisfied_VBN
by_PIN
the_DT
issue_NN
of_PIN
new_JJ
Ordinary_NN
Shares_NN
or_CC
by_PIN
existing_VBG
Ordinary_NN
Shares_NN
purchased_VBD
in_PIN
the_DT
market_NN
._.
The_DT
Remuneration_NOMZ
Committee_NN
sets_VPRT
the_DT
policy_NN
for_PIN
the_DT
Companys_NN
operation_NOMZ
of_PIN
the_DT
plan_NN
including_VBG [WZPRES]
as_IN
regards_VPRT
whether_IN
any_QUAN
performance_NN
target_NN
s_PRP
will_PRMD
apply_VB
to_PIN
the_DT
grant_NN
and_CC
or_CC
exercise_NN
of_PIN
each_QUAN
eligible_JJ
employees_NN
option_NOMZ
._.
Options_NOMZ
normally_RB
lapse_NN
on_PIN
cessation_NOMZ
of_PIN
employment_NOMZ
._.
Exercise_NN
is_VPRT
,_,
however_CONJ
,_,
permitted_VBD
for_PIN
a_DT
limited_JJ
period_NN
following_VBG [WZPRES]
cessation_NOMZ
of_PIN
employment_NOMZ
either_CC
for_PIN
reasons_NN
of_PIN
injury_NN
or_CC
disability_NOMZ
,_,
redundancy_NN
or_CC
retirement_NOMZ
,_,
or_CC
at_PIN
the_DT
discretion_NOMZ
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
and_ANDC
on_PIN
an_DT
amalgamation_NOMZ
,_,
take-over_NN
or_CC
winding-up_NN
of_PIN
the_DT
Company_NN
._.
2_CD
Summary_NN
of_PIN
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
and_CC
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Plan_NN
The_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
was_VBD [BYPA]
approved_VBN
by_PIN
shareholders_NN
in_PIN
1994_CD
for_PIN
a_DT
period_NN
of_PIN
10_CD
years_NN
._.
The_DT
last_JJ
grant_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
scheme_NN
was_VBD [PASS]
made_VBN
in_PIN
September_NN
2002_CD
._.
In_PIN
2003_CD
,_,
shareholders_NN
approved_VBD
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Plan_NN
for_PIN
a_DT
period_NN
of_PIN
10_CD
years_NN
._.
The_DT
first_JJ
grant_NN
of_PIN
options_NOMZ
under_IN
this_DEMO
plan_NN
was_VBD [PASS]
made_VBN
in_PIN
September_NN
2003_CD
._.
The_DT
following_JJ
sections_NOMZ
apply_VPRT
to_PIN
both_DT
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
and_CC
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Plan_NN
,_,
which_WDT [SERE]
have_VPRT
broadly_RB
similar_JJ
rules_NN
._.
Eligibility_NOMZ
UK_NN
resident_NN
employees_NN
of_PIN
participating_VBG
AstraZeneca_NN
companies_NN
are_VPRT [BEMA]
automatically_RB
eligible_PRED
to_TO
participate_VB
._.
Grant_NN
of_PIN
options_NOMZ
Invitations_NOMZ
to_TO
apply_VB
for_PIN
options_NOMZ
may_POMD
be_VB [PASS]
issued_VBN
within_PIN
six_CD
weeks_NN
after_IN
the_DT
announcement_NOMZ
by_PIN
the_DT
Company_NN
of_PIN
its_PIT
results_NN
for_PIN
any_QUAN
period_NN
and_CC
at_PIN
other_JJ
times_NN
in_PIN
circumstances_NN
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
exceptional_PRED
by_PIN
the_DT
Directors_NN
._.
No_SYNE
invitations_NOMZ
may_POMD
be_VB [PASS]
issued_VBN
later_TIME
than_PIN
10_CD
years_NN
after_IN
the_DT
approval_NN
of_PIN
the_DT
scheme_NN
by_PIN
shareholders_NN
._.
Options_NOMZ
may_POMD [SPAU]
only_DWNT
be_VB [PASS]
granted_VBN [SUAV]
to_PIN
employees_NN
who_WP [WHSUB]
enter_VPRT
into_PIN
UK_NN
Inland_NN
Revenue_NN
approved_VBD
savings_GER
contracts_NN
with_PIN
the_DT
savings_GER
body_NN
nominated_VBN [WZPAST]
by_PIN
the_DT
Company_NN
,_,
under_IN
which_WDT
monthly_JJ
savings_GER
of_PIN
a_DT
fixed_VBN
amount_NN
currently_RB
not_XX0
less_JJ
than_PIN
5_CD
nor_SYNE
more_EMPH
than_PIN
250_CD
are_VPRT [PASS]
made_VBN
over_RP
a_DT
period_NN
of_PIN
three_CD
or_CC
five_CD
years_NN
._.
The_DT
number_NN
of_PIN
Ordinary_NN
Shares_NN
over_IN
which_WDT
an_DT
option_NOMZ
is_VPRT [PASS]
granted_VBN [SUAV]
will_PRMD
be_VB [BEMA]
such_OSUB
that_NULL
the_DT
total_JJ
amount_NN
payable_JJ
on_PIN
its_PIT
exercise_NN
will_PRMD
be_VB [BEMA]
the_DT
proceeds_NN
on_PIN
maturity_NOMZ
of_PIN
the_DT
related_JJ
savings_GER
contract_NN
._.
No_SYNE
payment_NOMZ
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
for_PIN
the_DT
grant_NN
of_PIN
an_DT
option_NOMZ
._.
Individual_JJ
participation_NOMZ
Monthly_JJ
savings_GER
by_PIN
an_DT
employee_NN
under_IN
all_QUAN
savings_GER
contracts_NN
linked_VBN [WZPAST]
to_PIN
options_NOMZ
granted_VBN [SUAV]
under_IN
any_QUAN
SAYE_NN
scheme_NN
may_POMD
not_XX0
exceed_VB
250_CD
or_CC
such_JJ
lower_JJ
amounts_NN
as_IN
may_POMD
be_VB [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Directors_NN
._.
Acquisition_NOMZ
price_NN
The_DT
price_NN
per_PIN
Ordinary_NN
Share_NN
payable_JJ
upon_PIN
the_DT
exercise_NN
of_PIN
an_DT
option_NOMZ
will_PRMD
not_XX0
normally_RB
be_VB [BEMA]
less_PRED
than_PIN
the_DT
higher_JJ
of_PIN
:_:
a_DT
90_CD
%_NN
of_PIN
the_DT
arithmetical_JJ
average_NN
of_PIN
the_DT
middle-market_JJ
quotations_NOMZ
for_PIN
an_DT
Ordinary_NN
Share_NN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
on_PIN
three_CD
consecutive_JJ
dealing_VBG
days_NN
shortly_TIME
before_IN
the_DT
date_NN
on_PIN
which_WDT [PIRE]
invitations_NOMZ
to_TO
apply_VB
for_PIN
options_NOMZ
are_VPRT [PASS]
issued_VBN
provided_VBN
that_DEMO
no_SYNE
such_JJ
day_NN
may_POMD
fall_VB
before_IN
the_DT
Company_NN
last_JJ
announced_VBD [PUBV]
its_PIT
results_NN
for_PIN
any_QUAN
period_NN
or_CC
such_JJ
other_JJ
dealing_VBG
day_NN
or_CC
days_NN
falling_VBG [WZPRES]
within_PIN
the_DT
six_CD
week_NN
period_NN
for_PIN
the_DT
issue_NN
of_PIN
invitations_NOMZ
as_IN
the_DT
Directors_NN
may_POMD
decide_VB [SUAV] [PRIV]
:_:
and_ANDC
b_NN
the_DT
nominal_JJ
value_NN
of_PIN
an_DT
Ordinary_NN
Share_NN
unless_COND
the_DT
option_NOMZ
is_VPRT [PASS]
expressed_VBN
to_TO
relate_VB
only_DWNT
to_TO
existing_VBG
Ordinary_NN
Shares_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
107_CD
29_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
continued_VBD
Exercise_NN
of_PIN
options_NOMZ
An_DT
option_NOMZ
will_PRMD [SPAU]
normally_RB
be_VB [BEMA]
exercisable_JJ
only_DWNT
for_PIN
six_CD
months_NN
commencing_VBG [WZPRES]
on_PIN
the_DT
third_JJ
or_CC
fifth_JJ
anniversary_NN
of_PIN
the_DT
commencement_NOMZ
of_PIN
the_DT
related_JJ
savings_GER
contract_NN
._.
Options_NOMZ
are_VPRT [BYPA]
satisfied_VBN
by_PIN
the_DT
issue_NN
of_PIN
new_JJ
Ordinary_NN
Shares_NN
._.
Exercise_NN
is_VPRT
,_,
however_CONJ
,_,
permitted_VBD
for_PIN
a_DT
limited_JJ
period_NN
irrespective_RB
of_PIN
the_DT
period_NN
during_PIN
which_WDT [PIRE]
the_DT
option_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
held_VBN [PRIV]
following_VBG
cessation_NOMZ
of_PIN
employment_NOMZ
in_PIN
certain_JJ
compassionate_JJ
circumstances_NN
or_CC
where_RB
an_DT
option_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
held_VBN [PRIV]
for_PIN
more_EMPH
than_PIN
three_CD
years_NN
except_PIN
on_PIN
dismissal_NN
for_PIN
misconduct_NN
and_CC
on_PIN
an_DT
amalgamation_NOMZ
,_,
take-over_NN
or_CC
winding-up_NN
of_PIN
the_DT
Company_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
chosen_VBN
to_PIN
avail_NN
itself_PIT
of_PIN
the_DT
exemption_NOMZ
to_PIN
application_NOMZ
of_PIN
UITF17_NN
to_PIN
its_PIT
SAYE_NN
schemes_NN
._.
3_CD
Summary_NN
of_PIN
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
The_NN
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
was_VBD [PASS]
introduced_VBN
in_PIN
1994_CD
._.
The_DT
last_JJ
date_NN
for_PIN
the_DT
grant_NN
of_PIN
options_NOMZ
was_VBD [BEMA]
16_CD
March_NN
2000_CD
and_CC
the_DT
scheme_NN
has_VPRT [PEAS]
been_VBN [BYPA]
replaced_VBN
by_PIN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
._.
Options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
1994_CD
scheme_NN
are_VPRT [BEMA]
normally_RB
exercisable_PRED
between_PIN
three_CD
and_CC
10_CD
years_NN
following_VBG [WZPRES]
grant_NN
,_,
provided_VBD
the_DT
relevant_JJ
performance_NN
condition_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
satisfied_VBN
._.
The_DT
performance_NN
condition_NOMZ
applicable_JJ
to_PIN
the_DT
1994_CD
scheme_NN
was_VBD
that_DEMO
earnings_GER
per_PIN
share_NN
must_NEMD
have_VB [PEAS]
grown_VBN
by_PIN
at_PIN
least_JJ
the_DT
increase_NN
in_PIN
the_DT
UK_NN
Retail_NN
Price_NN
Index_NN
over_IN
three_CD
years_NN
plus_PIN
3_CD
%_NN
per_PIN
annum_NN
._.
Satisfaction_NOMZ
of_PIN
this_DEMO
condition_NOMZ
was_VBD [PASS]
tested_VBN
annually_RB
by_PIN
reference_NN
to_PIN
the_DT
audited_JJ
financial_JJ
statements_NOMZ
._.
All_QUAN
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
1994_CD
scheme_NN
have_VPRT [PEAS]
become_VBN
exercisable_JJ
,_,
the_DT
performance_NN
conditions_NOMZ
having_VBG [WZPRES] [PEAS]
been_VBN [PASS]
satisfied_VBN
._.
4_CD
Summary_NN
of_PIN
the_DT
Astra_NN
Shareholder_NN
Value_NN
Incentive_NN
Plan_NN
In_PIN
1996_CD
,_,
Astra_NN
established_VBD [PRIV]
a_DT
stock_NN
option_NOMZ
plan_NN
for_PIN
some_QUAN
100_CD
Astra_NN
employees_NN
in_PIN
key_JJ
senior_JJ
positions_NOMZ
._.
The_DT
plan_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
used_VBN
for_PIN
the_DT
grant_NN
of_PIN
options_NOMZ
and_CC
has_VPRT [PEAS]
been_VBN [BYPA]
superseded_VBN
by_PIN
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
._.
On_PIN
completion_NOMZ
of_PIN
the_DT
merger_NN
with_PIN
Zeneca_NN
,_,
options_NOMZ
in_PIN
Astra_NN
shares_NN
granted_VBN [SUAV]
under_IN
the_DT
plan_NN
were_VBD [BYPA]
replaced_VBN
by_PIN
options_NOMZ
to_TO
acquire_VB
a_DT
number_NN
of_PIN
AstraZeneca_NN
Ordinary_NN
Shares_NN
based_VBN [WZPAST]
on_PIN
the_DT
exchange_NN
ratio_NN
used_VBN [WZPAST]
in_PIN
the_DT
exchange_NN
offers_VPRT
used_VBN
to_TO
effect_VB
the_DT
AstraZeneca_NN
merger_NN
._.
The_DT
ratio_NN
of_PIN
AstraZeneca_NN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
in_PIN
respect_NN
of_PIN
former_JJ
Astra_NN
options_NOMZ
was_VBD [BEMA]
0.5045_CD
AstraZeneca_NN
options_NOMZ
for_PIN
each_QUAN
Astra_NN
option_NOMZ
held_VBD [PRIV]
._.
5_CD
Summary_NN
of_PIN
the_DT
Zeneca_NN
1993_CD
Senior_JJ
Staff_NN
Share_NN
Option_NOMZ
Scheme_NN
The_NN
Zeneca_NN
1993_CD
Senior_JJ
Staff_NN
Share_NN
Option_NOMZ
Scheme_NN
was_VBD [PASS]
introduced_VBN
at_PIN
the_DT
time_NN
of_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
from_PIN
ICI_NN
in_PIN
1993_CD
._.
The_DT
last_JJ
date_NN
for_PIN
the_DT
grant_NN
of_PIN
options_NOMZ
was_VBD [BEMA]
19_CD
May_POMD
1994_CD
and_CC
the_DT
scheme_NN
was_VBD [BYPA]
replaced_VBN
by_PIN
the_DT
Zeneca_NN
1994_CD
Executive_NN
Share_NN
Option_NOMZ
Scheme_NN
._.
At_PIN
31_CD
December_NN
2004_CD
,_,
there_EX
were_VBD
no_SYNE
options_NOMZ
outstanding_JJ
under_IN
this_DEMO
scheme_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
108_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
29_CD
Employee_NN
costs_NN
and_PHC
share_NN
option_NOMZ
plans_NN
for_PIN
employees_NN
continued_VBD
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
1994_CD
Scheme_NN
SAYE_NN
Schemes_NN
ASVIP_NN
Shares_NN
under_IN
Options_NOMZ
WAEP_NN
Options_NOMZ
WAEP_NN
Options_NOMZ
WAEP_NN
option_NOMZ
WAEP_NN
000_CD
pence_NN
000_CD
pence_NN
000_CD
pence_NN
000_CD
SEK_NN
At_PIN
1_CD
January_NN
2002_CD
Options_NOMZ
outstanding_JJ
11,399_CD
3236_CD
9,938_CD
2636_CD
2,799_CD
2459 965 375_CD
Movements_NOMZ
during_PIN
2002_CD
Options_NOMZ
granted_VBN [SUAV]
10,658_CD
3462_CD
2,721_CD
1756_CD
Options_NOMZ
exercised_VBN
22 3214 243 2175_CD
469 1888 206 317_CD
Options_NOMZ
forfeited_VBD
637 3298 406 2654_CD
986_CD
2735_CD
Options_NOMZ
lapsed_VBD
Weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
during_PIN
the_DT
year_NN
1186_CD
559_CD
At_PIN
31_CD
December_NN
2002_CD
Options_NOMZ
outstanding_JJ
21,398_CD
3347_CD
9,289_CD
2647_CD
4,065_CD
1987 759 391_CD
Movements_NOMZ
during_PIN
2003_CD
Options_NOMZ
granted_VBN [SUAV]
15,505_CD
2232 551 2211_CD
Options_NOMZ
exercised_VBN
52 2468 358 2423_CD
382 2137 151 311_CD
Options_NOMZ
forfeited_VBD
1,163_CD
3001 571 2695 282_CD
2192_CD
1_CD
318_CD
Options_NOMZ
lapsed_VBD
Weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
during_PIN
the_DT
year_NN
583_CD
658_CD
At_PIN
31_CD
December_NN
2003_CD
Options_NOMZ
outstanding_JJ
35,688_CD
2874_CD
8,360_CD
2654_CD
3,952_CD
1988 607 411_CD
Movements_NOMZ
during_PIN
2004_CD
Options_NOMZ
granted_VBN [SUAV]
10,741_CD
2529 550 2262_CD
Options_NOMZ
exercised_VBN
329 2787 586 2704_CD
113 2184 114 321_CD
Options_NOMZ
forfeited_VBD
1,964_CD
2886 285 2660 276_CD
2199_CD
10_CD
474_CD
Options_NOMZ
lapsed_VBD
Weighted_JJ
average_JJ
fair_JJ
value_NN
of_PIN
options_NOMZ
granted_VBN [SUAV] [WZPAST]
during_PIN
the_DT
year_NN
650_CD
632_CD
At_PIN
31_CD
December_NN
2004_CD
Options_NOMZ
outstanding_JJ
44,136_CD
2790_CD
7,489_CD
2650_CD
4,113_CD
2005 483 431_CD
Range_NN
of_PIN
exercise_NN
prices_NN
1913p_VPRT
to_TO
891p_VB
to_TO
1756p_VB
to_PIN
411SEK_CD
to_PIN
3487p_CD
2749p_CD
2971p_JJ
442SEK_NN
Weighted_NN
average_JJ
remaining_VBG
contractual_JJ
life_NN
2,852_CD
days_NN
1,814_CD
days_NN
1,058_CD
days_NN
258_CD
days_NN
Options_NOMZ
exercisable_JJ
10,706_CD
3203_CD
7,489_CD
2650 390 2373 483_CD
431_CD
Weighted_JJ
average_JJ
exercise_NN
price_NN
